Диссертация (1174253), страница 22
Текст из файла (страница 22)
– 2014. - №64 (4). –P. 248-257.61.Bloom B. Continuation of initial antihypertensive medication after 1 year oftherapy. / Bloom B. // Clinical Therapeutics. - 1998. - №20. – P. 671–681.62.Braam, B. Recognition and Management of Resistant Hypertension. / B. Braam,S. Taler, M. Rahman et al. // Clinical Journal of the American Society ofNephrology. –2017. - №12 (3). - P. 524-535.63.Bronsert, M. Comparative effectiveness of antihyperthensive therapeutic classesand treatment strategies in the initiation of therapy in primary care patients: aDistributed Ambulatory Research in Therapeutics Network (DARTNet) study.
/139M. Bronsert, W. Henderson, R. Valuck et al. // The Journal of the AmericanBoard of Family Medicine. - 2013. - №26. – P. 529–538.64.Catapano, A. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias./ A. L Catapano, I. Graham, G. Backer et al. // European Heart Journal. – 2016. №37 (39). - P. 2999- 3058.65.Chalmers, J. Effects of combination of perindopril, indapamide, and calciumchannel blockers in patients with type 2 diabetes mellitus: results from the ActionIn Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation(ADVANCE) trial.
/ J. Chalmers, H. Arima, M. Woodward et al. // Hypertension.- 2014. - №63. – P. 259–264.66.Coylewright, M. Menopause and hypertension: an age-old debate. / M.Coylewright, J. Reckelhoff, P. Ouyang. // Hypertension. - 2008. - №51. - P.952–959.67.Dahlof, B. Cardiovascular morbidity and mortality in the Losartan InterventionFor Endpoint reduction in hypertension study (LIFE): a randomised trial againstatenolol. / Dahlof B, Devereux RB, Kjeldsen SE et al.
// Lancet. – 2002. - №359.- P. 995–1003.68.Dahlof, B. Prevention of cardiovascular events with an antihypertensive regimenof amlodipine adding perindopril as required versus atenolol addingbendroflumethiazide as required, in the Anglo-Scandinavian Cardiac OutcomesTrial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomisedcontrolled trial. / B. Dahlof, P.S. Sever, N.R. Poulter et al. // Lancet. - 2005. №366. – P. 895–906.69.Deborde, T. Sex differences in antihypertensive treatment in France among17 856 patients in a tertiary hypertension unit.
/ T. Deborde, L. Amar, G. Bobrieet al. // Journal of Hypertension. – 2018. - №36 (4). – P. 939-946.70.Denton, K.M. Sex-Related Differences in Hypertension: Seek and Ye Shall Find./ K. M. Denton, L.M. Hilliard, M. Tare // Hypertension. – 2013. - №62. - P. 674–677.14071.Dessie, A. Adherence to antihypertensive treatment and associated factors amongpatients on follow up at University of Gondar Hospital, Northwest Ethiopia. / A.Dessie, G. Asres, S. Meseret et al. // BMC Public Health. – 2012.
- №12(1)[Электронныйресурс]–Режимдоступа:https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-12-282.72.Doumas, M. Gender differences in hypertension: myths and reality. / M. Doumas,V. Papademetriou, C. Faselis, P.Kokkinos. // Current Hypertension Reports. –2013. - № 15(4). - 321-330.73.Dubey, R. Sex hormones and hypertension. / R.
Dubey, S. Oparil, B. Imthurn,E. Jackson // Cardiovascular Research. – 2002. - №53. - P. 688–708.74.D sing, R. Pharmacological interventions into the renin–angiotensin system ithACinhibitors and angiotensin II receptor antagonists: effects beyond bloodpressure lo ering. / R. D sing // Therapeutic Advances in CardiovascularDisease. - 2016. - №10 (3). - P. 151–161.75.Ernst, G. Difference between apnea-hypopnea index (AHI) and oxygendesaturation index (ODI): proportional increase associated with degree of obesity./ G.
Ernst, M. Bosio, A. Salvado et al. // Sleep Breath. - 2016. - №4 (20). – С.1175-1183.76.Ettehad, D. Blood pressure lowering for prevention of cardiovascular disease anddeath: a systematic review and meta-analysis. / D. Ettehad, C. Emdin, A. Kiran etal. // Lancet. – 2016. - №387. – P. 957–967.77.Ferrari, R. Perindopril and Remodeling in Elderly with Acute MyocardialInfarction Investigators.
Effects of angiotensin- converting enzyme inhibitionwith perindopril on left ventricular remodeling and clinical outcome: results ofthe randomized Perindopril and Remodeling in Elderly with Acute MyocardialInfarction (PREAMI) Study. / R. Ferrari. // Archives of Internal Medicine. –2006. - №166 (6). -P. 659-666.78.Ferreire, S.A. Bradykinin-potentiating factor (BPF) present in the venom ofBothrops jararaca.
/ S.A. Ferreire. // British Journal of Pharmacology. – 1965. №24. – P. 163-169.14179.Forouzanfar, M. Global burden of hypertension and systolic blood pressure of atleast 110 to 115 mm Hg, 1990–2015. / M. Forouzanfar, P. Liu, G. Roth et al. //JAMA. - 2017. - №317. – P. 165–182.80.Fox, K. Efficacy of perindopril in reduction of cardiovascular events amongpatients with stable coronary artery disease: randomised, double-blind, placebocontrolled, multicentre trial (the EUROPA study).
/ K. Fox, J. Henderson, M.Bertrand et al. // Lancet. -2003. - №362 (9386). – P. 782-788.81.Gavras, H. Antihypertensive effect of the oral angiotensin convertingenzymeinhibitor SQ 14225 in man. / H. Gavras, H.R. Brunner, G.A. Turini et al. // NewEngland Journal of Medicine. – 1978. - №298 (18). – P. 991–995.82.GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke,1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.
/GBD 2016 Stroke Collaborators. // Lancet Neurology. – 2019. – P. 439-458.83.Ghembaza, M. Impact of patient knowledge of hypertension complications onadherence to antihypertensive therapy. / M. Ghembaza, Y. Senoussaoui, M. Tani,et al. // Current Hypertension Reviews. – 2014. - №10. – С. 41–48.84.Giralt, D.
The gender gap in stroke: a meta-analysis. / D. Giralt, S. DominguesMontanari, M. Mendioroz et al. // Acta Neurol Scand. – 2012. - №125 (2). – P.83-90.85.Gouni-Berthoid, H.R. Management of Blood Pressure and Heart Rate in Patientswith Diabetes Mellitus.
/ H.R. Gouni-Berthoid, L. Ravarani, H. Berthold. //Current Pharmaceutical Design. – 2017. - №23 (31). - P. 4573-4582.86.Grimmsmann, T. Comparison of therapy persistence for fixed versus freecombinationantihypertensives:aretrospectivecohortstudy./T.Grimmsmann, W. Himmel. // BMJ Open 2016. - №6 (11). [Электронныйресурс] – Режим доступа: https://bmjopen.bmj.com/content/6/11/e011650.long.87.Hajar, R. Framingham Contribution to Cardiovascular Disease. / R. Hajar // HeartViews.
- 2016. - №17 (2). - P. 78-81.88.Hamood, H. Effect of adherence to evidence‐based therapy after acutemyocardial infarction on all‐cause mortality. / H. Hamood, R. Hamood, M.S.142Green et al. // Pharmacoepidemiology and Drug Safety. – 2015. - №24 (10). –P.1093-1104.89.Hansen, T.W. Diagnostic Thresholds for Ambulatory Blood Pressure MovingLower: A Review Based on a Meta_Analysis – Clinical Implications. / T.W.Hansen, M. Kikuya, L. Thijs et al. // Journal of Clinical Hypertension.(Greenwich). – 2008. - №10(5).
– P. 377–381.90.Haynes, R.B. Strategies to improve compliance with referrals, appointments, andprescribed medical regimens. In Compliance in Health Care. / edited by R.B.Haynes, D.W. Taylor, D.L. Sackett. - Baltimore: Johns Hopkins University Press,1979. –P. 121.91.Hsia, J. Prehypertension and cardiovascular disease risk in the Women's HealthInitiative.
/ J. Hsia, K. Margolis, C. Eaton et al. // Circulation. – 2007. - №115. –P. 855–860.92.Hwang, A.Y. Trends in Antihypertensive Medication Use Among US PatientsWith Resistant Hypertension, 2008 to 2014. / A.Y. Hwang, C. Dave, S.M. Smith// Hypertension. – 2016. - №68 (6). – P. 1349-1354.93.Jicheng, L.
Antihypertensive agents for preventing diabetic kidney disease. / L.Jicheng, V. Perkovic, C.V. Foote et al // Cochrane Database of SystematicReviews. 2012. – V. 12. - [Электронный ресурс] – Режим доступа:https://doi.org/10.1002/14651858.CD004136.pub394.Julius, S. Outcomes in hypertensive patients at high cardiovascular risk treatedwith regimens based on valsartan or amlodipine: the VALUE randomised trial.
/S. Julius, S.E. Kjeldsen, M. Weber et al. // Lancet. – 2004. - №363. – P. 2022–2031.95.Kario, K. Time for focus on morning hypertension. Pitfall of currentantihypertensive medication. / K. Kario. // American journal of hypertension. 2005. - №18. – P. 149-151.96.Katsi, V. Arterial Hypertension and Health-Related Quality of Life.
/ V. Katsi,M. Kallistratos, K. Kontoangelos et al. // Frontiers in Psychiatry. - 2017. - №8. –143[Электронныйресурс].-Режимдоступа:https://doi.org/10.3389/fpsyt.2017.00270.97.Kawalec, P. Effectiveness of fixed-dose combination therapy in hypertension:systematic review and meta-analysis. / P. Kawalec, P. Holko, M. Gawin, A. Pilc// Archives of Medical Science. – 2018. - №14 (5). – P. 1125–1136.98.Kishore, S. Fixed-dose combinations for hypertension.
/ S. Kishore, A. Salam, A.Rodgers et al. // Lancet. - 2018. - №392. – P. 819-820.99.Kouvari, M. Attica Greecs Studies Investigators; Gender-specific, Lifestylerelated Factors and 10-year Cardiovascular Disease Risk; the ATTICA andGREECS Cohort Studies. / M. Kouvari, D.B. Panagiotakos, C. Chrysohoou et al.// Current vascular pharmacology. – 2019. - №17 (4).
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
